https://pubs.rsna.org/doi/pdf/10.1148/rycan.2021210038

COVID-19 Vaccination-Related Lymphadenopathy: What To Be Aware Of.

Cancer patients are at a high risk of being infected with COVID-19 and have poor prognosis after infection. Breast cancer is one the most common cancers. Since vaccination is an effective measure to prevent the spread of COVID-19, we studied the vaccination rate among breast cancer survivors and analyzed their characteristics to provide evidence for boosting the vaccination rate. The researchers conducted a multicenter, cross-sectional study on 747 breast cancer survivors from six hospitals in Wuhan city between June 5 and June 12, 2021. Self-administrated questionnaires based on relevant studies were distributed. The researchers then compared differences in characteristics among vaccinated patients, hesitant patients, and non-vaccinated patients. Moreover, they performed univariable and multivariable logistic regression analyses to identify potential factors associated with vaccination hesitancy. The researchers assessed a total of 744 breast cancer survivors; 94 cases in the vaccinated group, 103 in the planning group, 295 in the hesitancy group, and 252 in the refusal group. The vaccination rate was 12.63% (95% confidence interval [CI] 10.25% to 15.02%), and 37.23% (95% CI 27.48% to 47.82%) patients reported adverse reactions. The vaccination hesitancy/refusal rate was 73.52% (95% CI 70.19% to 76.66%), which was independently associated with current endocrine or targeted therapy (OR=1.52, 95% CI 1.03-2.24), no notification from communities or units (OR=2.46, 95% CI 1.69-3.59) and self-perceived feel (general vs good, OR=1.46, 95%CI 1.01-2.13; bad vs good, OR=4.75, 95%CI 1.85-12.16). In hesitancy/refusal group, the primary reasons were “I did not know who to ask whether I can get vaccinated” (46.07%), opinions of doctors in charge of treatment (35.83%) and doctors in charge of vaccination (17.55%) would influence patients’ decision to vaccination. Researchers observed COVID-19 vaccine hesitancy among breast cancer survivors. Targeted patients at a high risk of infection were vaccine hesitant. Effective interaction between doctors and patients, simple and consistent practical guidelines on vaccination, and timely and positive information from authoritative media could combat misinformation and greatly reduce vaccine hesitancy among breast cancer survivors.

Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China.

There have been recent reports in the breast imaging literature of unilateral axillary lymphadenopathy following COVID-19 vaccination. It is unclear whether the reactive lymphadenopathy may impact the sentinel lymph node biopsy procedure. In this article, we provide guidelines regarding the timing of the COVID-19 vaccine and breast cancer surgery which were formulated after a review of the available literature and in consultation with infectious disease specialists.

/pdf/covid-19-vaccination-and-breast-cancer-surgery-timing-200wpjgt2p.pdf

COVID-19 vaccination and breast cancer surgery timing.

COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature

B-cell lymphomas are neoplastic diseases occasionally associated with chronic inflammation. mRNA vaccines for coronavirus disease 2019 (COVID-19) induce inflammatory responses, which often lead to fever and lymphadenopathies indistinguishable from lymphomas. Although both lymphadenopathies and lymphomas can be influential, the correlation between them is unclear. Herein, we present the first case of marginal zone B-cell lymphoma following mRNA COVID-19 vaccination. An 80-year-old Japanese woman presented with a right temporal mass that appeared the morning after she was administered her first mRNA COVID-19 vaccination (BNT162b2). The mass gradually decreased in size but persisted over 6 weeks after her first vaccination (3 weeks after her second vaccination). At her first visit to our hospital, ultrasound revealed the size of the mass to be 28.5 × 5.7 mm, and computed tomography revealed multiple lymphadenopathies in the right parotid, submandibular, jugular, and supraclavicular regions. Initially, we suspected head-and-neck benign lymphadenopathy as a side effect of vaccination. Nine weeks later, the number of swollen submandibular and parotid glands increased, and the lymph nodes further enlarged. Finally, the right temporal mass was diagnosed as marginal zone B-cell lymphoma based on immunohistochemical and flow cytometry findings of biopsy specimens. Our findings suggest that although 4–6 weeks of observation for lymph node inflammation after the second vaccination is recommended, malignancy should also be considered in the differential diagnosis of lymphadenopathy following vaccination.

/pdf/rapid-progression-of-marginal-zone-b-cell-lymphoma-after-1spymgki.pdf

Rapid progression of marginal zone B-cell lymphoma after COVID-19 vaccination (BNT162b2): A case report

https://journals.sagepub.com/doi/pdf/10.1177/0846537121998949

The Canadian Society of Breast Imaging Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination - Update.

Michael H. Barry

Papers

The Canadian Society of Breast Imaging Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination - Update.